A PHASE 1, RANDOMIZED, 2-WAY CROSSOVER, MULTIPLE-DOSE, OPEN-LABEL STUDY TO ESTIMATE THE EFFECT OF PF-04965842 ON ROSUVASTATIN PHARMACOKINETICS IN HEALTHY PARTICIPANTS
Latest Information Update: 04 Apr 2022
At a glance
- Drugs Abrocitinib (Primary) ; Rosuvastatin
- Indications Atopic dermatitis; Prurigo nodularis; Pruritus
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 28 Mar 2022 Results published in the Clinical Pharmacology and Therapeutics
- 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 02 May 2019 Status changed from recruiting to completed.